Crinetics Pharmaceuticals (CRNX) Accumulated Depreciation & Amortization (2017 - 2025)
Historic Accumulated Depreciation & Amortization for Crinetics Pharmaceuticals (CRNX) over the last 9 years, with Q3 2025 value amounting to $7.0 million.
- Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization rose 90.26% to $7.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.0 million, marking a year-over-year increase of 90.26%. This contributed to the annual value of $7.7 million for FY2024, which is 5256.51% up from last year.
- Latest data reveals that Crinetics Pharmaceuticals reported Accumulated Depreciation & Amortization of $7.0 million as of Q3 2025, which was up 90.26% from $9.6 million recorded in Q2 2025.
- In the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization registered a high of $9.6 million during Q2 2025, and its lowest value of $2.9 million during Q1 2021.
- Over the past 5 years, Crinetics Pharmaceuticals' median Accumulated Depreciation & Amortization value was $4.7 million (recorded in 2023), while the average stood at $5.3 million.
- Data for Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY increase of 5772.18% (in 2025) and a maximum YoY decrease of 90.26% (in 2025) over the last 5 years.
- Over the past 5 years, Crinetics Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $3.5 million in 2021, then increased by 17.36% to $4.1 million in 2022, then increased by 24.09% to $5.1 million in 2023, then soared by 52.57% to $7.7 million in 2024, then fell by 8.91% to $7.0 million in 2025.
- Its Accumulated Depreciation & Amortization was $7.0 million in Q3 2025, compared to $9.6 million in Q2 2025 and $8.6 million in Q1 2025.